The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-Cell cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 538-548

  Coffey, Greg ^a   Betz, Andreas ^a   DeGuzman, Francis ^a   Pak, Yvonne ^a   Inagaki, Mayuko ^a   Baker, Dale C ^a   Hollenbach, Stanley J ^a   Pandey, Anjali ^a   Sinha, Uma ^a  

^a Portola Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINOCYCLOHEXYLAMINO) 4 (3 TOLYLAMINO)PYRIMIDINE 5 CARBOXAMIDE; BIIB 057; CERDULATINIB; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; JANUS KINASE INHIBITOR 1; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; T LYMPHOCYTE RECEPTOR; TOFACITINIB; UNCLASSIFIED DRUG; 4-(CYCLOPROPYLAMINO)-2-((4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDINE-5-CARBOXAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; B-CELL LYMPHOMA CELL LINE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; SPLENOMEGALY; T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ARTHRITIS, EXPERIMENTAL; BAGG ALBINO MOUSE; BOVINAE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LEWIS RAT; LYMPHOMA, B-CELL; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNITY; CATTLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; SULFONES; TREATMENT OUTCOME;

EID: 84908428541     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218164     Document Type: Article

References (62)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, and Yu X, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
2. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, and Scharenberg AM (1999) SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 274:32662-32666.
3. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, and Young C, et al. (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319:998-1008.
4. Braun D, Caramalho I, and Demengeot J (2002) IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 14:411-419.
5. Brown JR, Furman RR, Flinn I, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SEF, Benson DM, Peterman S, and Johnson DM, et al. (2013) Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. J Clin Oncol 31 (Suppl) 7003.
6. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, and Zirlik K (2010) Spleen tyrosine kinase inhibition prevents chemokine-and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115:4497-4506.
7. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, and Wierda WG, et al. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42.
8. Castejón R, Vargas JA, Romero Y, Briz M, Muñoz RM, and Durántez A (1999) Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Cytometry 38:224-230.
9. Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, and Wang YL (2011) SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 118:6342-6352.
10. Chiorazzi N, Hatzi K, and Albesiano E (2005) B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto) antigens. Ann N Y Acad Sci 1062:1-12.
11. Clark EA, Shu GL, Lüscher B, Draves KE, Banchereau J, Ledbetter JA, and Valentine MA (1989) Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol 143:3873-3880.
12. Coffey G, Betz A, Graf J, Stephens G, Lin PH, Imboden J, and Sinha U (2013) Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis. Pharmacology Research and Perspectives 1:1-11.
13. Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, and Baker D, et al. (2012) Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 340:350-359.
14. Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, and Tarakhovsky A, et al. (2010) Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 185:1532-1543.
15. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, and Sarfati M (1992) Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176:1319-1326.
16. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, and Yang Y, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92.
17. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, and Ye BH (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111:1515-1523.
18. Dühren-von Minden M, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M, and Köhler F,, et al. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:309-312.
19. el-Far M, Fouda M, Yahya R, and el-Baz H (2004) Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 60:253-258.
20. Elliott ER, Van Ziffle JA, Scapini P, Sullivan BM, Locksley RM, and Lowell CA (2011) Deletion of Syk in neutrophils prevents immune complex arthritis. J Immunol 187:4319-4330.
21. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, and Kurzrock R (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97:256-263.
22. Flinn IW, Patel M, Wagner-Johnston N, Pandey A, Coffey G, Leeds J, Hollenbach SJ, Levy G, and Curnutte J(2014) Pharmacokinetics and pharmacodynamics of the dual Syk/Jak inhibitor PRT062070 (Cerdulatinib) in patients with advanced B cell malignancies. J Clin Oncol 32 (Suppl):5s.
23. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, and Favata MF, et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298-5307.
24. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, and Leonard JP, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578-2585.
25. Frommhold D, Mannigel I, Schymeinsky J, Mocsai A, Poeschl J, Walzog B, and Sperandio M (2007) Spleen tyrosine kinase Syk is critical for sustained leukocyte adhesion during inflammation in vivo. BMC Immunol 8:31.
26. Gabay C, Ben-Bassat H, Schlesinger M, and Laskov R (1999) Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Haematol 63:180-191.
27. Hatton O, Lambert SL, Krams SM, and Martinez OM (2012) Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas. PLoS ONE 7:e42610.
28. Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, and Yamashita M, et al. (2013) A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol 31 (Suppl): 8523.
29. Jakus Z, Simon E, Balázs B, and Mócsai A (2010) Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum 62:1899-1910.
30. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, and Goldstone AH (1994) Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 88:268-274.
31. Jiang A, Craxton A, Kurosaki T, and Clark EA (1998) Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med 188:1297-1306.
32. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, and Usmani SZ, et al. (2013) A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 19:3659-3670.
33. Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, and Albitar M (2002) Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95:1071-1075.
34. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, and Staudt LM (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713.
35. Ma J, Coffey G, Lu P, Cheng S, Guo A, Pandey A, and Wang YL(2013) Dual SYK/JAK inhibition has a broader anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Blood 122: 1833.
36. Mahadevan D, Choi J, Cooke L, Simons B, Riley C, Klinkhammer T, Sud R, Maddipoti S, Hehn S, and Garewal H, et al. (2009) Gene expression and serum cytokine profiling of low stage CLL identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as regulators of cell proliferation, Survival and Migration. Hum Genomics Proteomics 2009:453634.
37. Mócsai A, Ruland J, and Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10:387-402.
38. Mócsai A, Zhou M, Meng F, Tybulewicz VL, and Lowell CA (2002) Syk is required for integrin signaling in neutrophils. Immunity 16:547-558.
39. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, and Aguiar RC, et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861.
40. Mountz JD, Smith J, Snapper CM, Mushinski JF, and Finkelman FD (1987) Polyclonal activation of the murine immune system by an antibody to IgD. VIII. Stimulation of IgD secretion. J Immunol 139:2172-2178.
41. Ozaki N, Suzuki S, Ishida M, Harada Y, Tanaka K, Sato Y, Kono T, Kubo M, Kitamura D, and Encinas J, et al. (2012) Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anticollagen antibody-induced arthritis. Int Immunol 24:539-550.
42. Panayiotidis P, Ganeshaguru K, Jabbar SA, and Hoffbrand AV (1993) Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 85:439-445.
43. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, and Harness JA (2012) Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167:668-677.
44. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, and Brahn E (2007) Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 124:244-257.
45. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, and Bussel JB (2009) Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113:3154-3160.
46. Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, and Bergmeier W, et al. (2011) PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 117:2241-2246.
47. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, and Giltnane JM, et al.; Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947.
48. Sharman JP, Klein L, Boxer M, Kolibaba KS, Hawkins MJ, Di Paolo JA, Hu J, Reddy A, Jin F, and Melchor-Khan F, et al. (2013) Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL) and non-hodgkin lymphoma (NHL). Blood 642:1634.
49. Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, and Baker D, et al. (2013) The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther 344:378-387.
50. Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, Samuel ER, and Wickremasinghe RG (2010) The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 116:4569-4577.
51. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, and Weimar W, et al. (2012) Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 12:2446-2456.
52. Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow SO, Bongiovanni KF, Korsmeyer SJ, and Greene WC (1984) Expression of interleukin 2 receptors on activated human B cells. J Exp Med 160:1450-1466.
53. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, and Williams ME, et al. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507-516.
54. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, and Vicente-Gonzales AV, et al. (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58:3309-3318.
55. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, and Magilavy DB (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363:1303-1312.
56. Wex E, Bouyssou T, Duechs MJ, Erb KJ, Gantner F, Sanderson MP, Schnapp A, Stierstorfer BE, and Wollin L (2011) Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo. Eur J Immunol 41:3208-3218.
57. Wilson WH, Gerecitano JF, Goy A, Vos S, Kenkre VP, Barr PM, Blum KA, Shustov AR, Advani RH, and Lih J, et al. (2012) The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 120:686.
58. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, and Staudt LM (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100:9991-9996.
59. Yamaoka K, Saharinen P, Pesu M, Holt VE, 3rd, Silvennoinen O, and O'Shea JJ (2004) The Janus kinases (Jaks). Genome Biol 5:253.
60. Yan XJ, Dozmorov I, Li W, Yancopoulos S, Sison C, Centola M, Jain P, Allen SL, Kolitz JE, and Rai KR, et al. (2011) Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 118:5201-5210.
61. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, and de Castro Faria S, et al. (2012) Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 30:4161-4167.
62. Zubler RH, Lowenthal JW, Erard F, Hashimoto N, Devos R, and MacDonald HR (1984) Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med 160:1170-1183.